| Dr Jason Edward Holmes, OD | |
|
1553 W 9000 S, West Jordan, UT 84088-9219 | |
| (801) 561-7300 | |
| (801) 561-7300 |
| Full Name | Dr Jason Edward Holmes |
|---|---|
| Gender | Male |
| Speciality | Optometry |
| Experience | 33 Years |
| Location | 1553 W 9000 S, West Jordan, Utah |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1194776005 | NPI | - | NPPES |
| 410985054103 | Medicaid | UT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 114312-9934 (Utah) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Davis Vision Center Associates Pllc | 0446388805 | 3 |
News Archive
Thanks to a discovery by scientists at Robarts Research Institute and The University of Western Ontario, patients undergoing peritoneal dialysis may soon be able to worry less about the risks of infection and lessen their hospital stays.
Ventas, Inc. said today that the United States District Court for the Western District of Kentucky has ruled that Ventas may immediately collect the $102 million compensatory damages judgment against HCP, Inc. that it was awarded by a federal jury in 2009.
In a clinical trial involving 18,924 patients from 57 countries who had suffered a recent heart attack or threatened heart attack, researchers at the University of Colorado Anschutz Medical Campus and fellow scientists around the world have found that the cholesterol-lowering drug alirocumab reduced the chance of having additional heart problems or stroke.
Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced the completion of patient enrollment in two randomized, double-masked, Phase 3 clinical trials evaluating VEGF Trap-Eye in the treatment of the neovascular form of age-related macular degeneration (wet AMD).
› Verified 2 days ago
| Provider Name | Davis Vision Center Associates Pllc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1689997165 PECOS PAC ID: 0446388805 Enrollment ID: O20100506000263 |
News Archive
Thanks to a discovery by scientists at Robarts Research Institute and The University of Western Ontario, patients undergoing peritoneal dialysis may soon be able to worry less about the risks of infection and lessen their hospital stays.
Ventas, Inc. said today that the United States District Court for the Western District of Kentucky has ruled that Ventas may immediately collect the $102 million compensatory damages judgment against HCP, Inc. that it was awarded by a federal jury in 2009.
In a clinical trial involving 18,924 patients from 57 countries who had suffered a recent heart attack or threatened heart attack, researchers at the University of Colorado Anschutz Medical Campus and fellow scientists around the world have found that the cholesterol-lowering drug alirocumab reduced the chance of having additional heart problems or stroke.
Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced the completion of patient enrollment in two randomized, double-masked, Phase 3 clinical trials evaluating VEGF Trap-Eye in the treatment of the neovascular form of age-related macular degeneration (wet AMD).
› Verified 2 days ago
| Provider Name | Glaukom Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1518307909 PECOS PAC ID: 0840421798 Enrollment ID: O20140318002035 |
News Archive
Thanks to a discovery by scientists at Robarts Research Institute and The University of Western Ontario, patients undergoing peritoneal dialysis may soon be able to worry less about the risks of infection and lessen their hospital stays.
Ventas, Inc. said today that the United States District Court for the Western District of Kentucky has ruled that Ventas may immediately collect the $102 million compensatory damages judgment against HCP, Inc. that it was awarded by a federal jury in 2009.
In a clinical trial involving 18,924 patients from 57 countries who had suffered a recent heart attack or threatened heart attack, researchers at the University of Colorado Anschutz Medical Campus and fellow scientists around the world have found that the cholesterol-lowering drug alirocumab reduced the chance of having additional heart problems or stroke.
Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced the completion of patient enrollment in two randomized, double-masked, Phase 3 clinical trials evaluating VEGF Trap-Eye in the treatment of the neovascular form of age-related macular degeneration (wet AMD).
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jason Edward Holmes, OD 1553 W 9000 S, West Jordan, UT 84088-9219 Ph: (801) 561-7300 | Dr Jason Edward Holmes, OD 1553 W 9000 S, West Jordan, UT 84088-9219 Ph: (801) 561-7300 |
News Archive
Thanks to a discovery by scientists at Robarts Research Institute and The University of Western Ontario, patients undergoing peritoneal dialysis may soon be able to worry less about the risks of infection and lessen their hospital stays.
Ventas, Inc. said today that the United States District Court for the Western District of Kentucky has ruled that Ventas may immediately collect the $102 million compensatory damages judgment against HCP, Inc. that it was awarded by a federal jury in 2009.
In a clinical trial involving 18,924 patients from 57 countries who had suffered a recent heart attack or threatened heart attack, researchers at the University of Colorado Anschutz Medical Campus and fellow scientists around the world have found that the cholesterol-lowering drug alirocumab reduced the chance of having additional heart problems or stroke.
Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced the completion of patient enrollment in two randomized, double-masked, Phase 3 clinical trials evaluating VEGF Trap-Eye in the treatment of the neovascular form of age-related macular degeneration (wet AMD).
› Verified 2 days ago
Dr. Kerry Allen Okelberry, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 6705 Redwood Rd, West Jordan, UT 84084 Phone: 801-268-0866 Fax: 801-268-2092 | |
Hau Andy Nguyen, OD Optometrist Medicare: Not Enrolled in Medicare Practice Location: 3857 West Campus View Drive, Suite 110, West Jordan, UT 84084 Phone: 801-601-3231 | |
Sheri Meyer O.d. Pllc Optometrist Medicare: Not Enrolled in Medicare Practice Location: 6705 S Redwood Rd, West Jordan, UT 84084 Phone: 801-268-0866 | |
Healthy Eyes For Life Optometrist Medicare: Medicare Enrolled Practice Location: 8806 Redwood Rd, Ste. 101, West Jordan, UT 84088 Phone: 801-578-2020 Fax: 801-748-4892 | |
Mobile Vision Consultants, Pc Optometrist Medicare: Not Enrolled in Medicare Practice Location: 7533 S Center View Ct Ste 4195, West Jordan, UT 84084 Phone: 775-375-8869 | |
Dr. Taylor Wade Blanco, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 7555 S Center View Ct Ste 101, West Jordan, UT 84084 Phone: 801-566-5683 | |
Rhett D. Veater, OD Optometrist Medicare: Not Enrolled in Medicare Practice Location: 1656 W 9000 S, West Jordan, UT 84088 Phone: 801-255-5454 Fax: 801-255-1109 |